People · Operator
Named in public records as an officer, director or promoter · active 2011–2014 · Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AVAXIA BIOLOGICS, Inc | — | Other Health Care | Series A | $28.2M | $20.3M | 2011 |
David S. Poorvin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David S. Poorvin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Henry S. Kay | 1 | 2 |
| Christopher S. Kiritsy | 1 | 2 |
| David H Donabedian | 1 | 2 |
| David C. Dlesk | 1 | 1 |
| Christopher F. Kiritsy | 1 | 1 |
| Eileen F. Bostwick | 1 | 1 |
| Jonathan S. Fleming | 1 | 1 |
| David S. Donabedian | 1 | 1 |
| Nada S. Jain | 1 | 1 |
| John S. Edwards | 1 | 1 |
| Robert S. Manning | 1 | 1 |
| Barbara S. Fox | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.